Clinical Trials Browser

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06277050 2024-04-30

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Phase 3 Recruiting

264 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06026878 2023-09-07

GNT Induction Treatment in Locally Advanced NPC

Phase 3 Recruiting

228 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05813626 2023-04-14

Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 2 Recruiting

89 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05229315 2023-04-13

PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma

Phase 2 Unknown

45 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04405622 2023-02-06

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Phase 2 Unknown

21 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05340491 2022-08-31

Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial

Phase 3 Recruiting

212 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05484375 2022-08-02

Capecitabine Plus Toripalimab Maintenance Therapy in Metastatic Nasopharyngeal Carcinoma After First-line Treatment

Phase 2 Not yet recruiting

40 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04073784 2022-04-26

Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Phase 1 Unknown

41 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05341193 2022-04-22

PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 1/2 Unknown

32 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT02915432 2021-12-13

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Phase 1/2 Unknown

401 enrolled 1 FDA

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma

NCT04992988 2021-08-20

Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial

Phase 2 Unknown

40 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04376866 2021-07-20

Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

Phase 3 Recruiting

204 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04955886 2021-07-09

Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 2 Unknown

14 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04778956 2021-03-04

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Phase 3 Recruiting

218 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT04453813 2020-09-28

Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Phase 3 Recruiting

226 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04447326 2020-06-25

Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

106 enrolled

Head & Neck

Nasopharyngeal Carcinoma